Sera Prognostics Reports Q4 and Full Year 2025 Financial Results: PRIME Study Publication, Commercial Progress, and Extended Cash Runway

Overview and Key Highlights

Sera Prognostics Inc. (Nasdaq: SERA), known as The Pregnancy Company®, has released its financial results for the fourth quarter and full year ended December 31, 2025. The company, focused on improving maternal and neonatal health through innovative pregnancy biomarker information, has also shared significant operational achievements and strategic updates that may have material implications for shareholders and the company’s valuation.

Key 2025 and Recent Highlights

• Landmark PRIME Study Published: In January 2026, the PRIME Study—a randomized controlled trial of 5,018 women—was published in the journal PREGNANCY. The study demonstrated that Sera’s PreTRM® blood test led to:
  • 56% fewer babies born before 32 weeks
  • 32% fewer babies born before 35 weeks
  • 20% reduction in NICU admissions
  • 20% reduction in odds of neonatal morbidity
  • One NICU day saved for every 4.2 patients screened

  These results provide strong, peer-reviewed evidence of PreTRM’s impact on early birth reduction and newborn complications.

• European Expert Commentary: In March, European experts published commentary in The Journal of Maternal-Fetal & Neonatal Medicine highlighting that current preterm birth prevention strategies in Europe fail to identify most women at risk. The commentary recognized the PreTRM approach as highly aligned with European healthcare needs, reinforcing its international potential.
• Commercial Progress in the U.S.:
  • Advanced commercial discussions with 10 commercial and Medicaid payers across 13 states for PreTRM program adoption.
  • The addition of a new partner, bringing total active partner programs to two.
  • Expansion of the U.S. commercial team with six additional field sales staff and a Head of Access, positioning the company for broader market engagement following PRIME Study publication.
• Global Expansion Preparation: Regulatory progress is ongoing for CE marking in Europe, with growing clinical validation and notable support from European expert commentary. PreTRM is positioned as a scalable, cost-effective solution for publicly funded healthcare systems.
• Successful Equity Financing: In February, Sera completed an underwritten public offering, including the full exercise of the underwriters’ option, raising approximately \$57.5 million in gross proceeds. This extends the company’s cash runway through 2028 and supports U.S. commercial expansion, EU market preparation, and broader market adoption initiatives.
• Leadership and Board Strengthening:
  • Dr. Tiffany Inglis appointed Chief Medical Officer in October 2025, bringing extensive clinical and payer-side leadership experience (Elevance Health, Carelon Health) to drive women’s and children’s health programs.
  • Lee Anderson joined as Chief Commercial Officer in May 2025, offering over three decades of leadership across sales, marketing, and strategic healthcare accounts.
  • Jeff Elliott appointed to the Board of Directors in March 2025, contributing expertise in corporate strategy, business operations, finance, and molecular diagnostics commercialization.

Financial Results

Fourth Quarter 2025

• Revenue: \$10,000 (down from \$24,000 in Q4 2024)
• Total Operating Expenses: \$9.0 million (down from \$9.4 million in Q4 2024)
• Research & Development Expenses: \$3.2 million (up slightly from \$3.1 million)
• Selling, General & Administrative Expenses: \$5.7 million (down from \$6.3 million)
• Net Loss: \$7.9 million (improved from \$8.6 million)

Full Year 2025

• Total Revenue: \$81,000 (up from \$77,000 in 2024)
• Total Operating Expenses: \$36.6 million (stable vs. \$36.7 million in 2024)
• Research & Development Expenses: \$13.2 million (down from \$14.7 million, reflecting a shift from clinical studies to commercialization)
• Selling, General & Administrative Expenses: \$23.3 million (up from \$21.9 million, due to targeted commercial investments and strategic hiring)
• Net Loss: \$31.9 million (narrowed from \$32.9 million in 2024)
• Cash, Cash Equivalents, and Marketable Securities: \$95.8 million as of December 31, 2025, expected to fund operations through 2028 and across key milestones.

Strategic and Shareholder Implications

• PRIME Study Publication: The publication of the PRIME Study is a significant milestone, providing robust clinical validation for the PreTRM test and strengthening the value proposition for payers and healthcare providers. This could accelerate commercial adoption and payer coverage, directly impacting future revenues and the company’s valuation.
• Commercial and Regulatory Expansion: The company’s progress in both U.S. and European markets, combined with advanced payer discussions and regulatory efforts, positions Sera for potential revenue inflection points as adoption scales.
• Financial Position: The successful financing and extended cash runway reduce near-term capital risk and support the company’s commercialization and expansion strategies.
• Leadership Strengthening: The addition of experienced executives and board members is likely to enhance operational execution and market penetration efforts.
• Risks: Sera notes that revenues are still minimal and largely dependent on the PreTRM test. Risks include: the need for broad market and scientific acceptance, dependence on a limited number of customers, reimbursement and regulatory uncertainties, and potential competition. The company highlights these as forward-looking risks.

About Sera Prognostics and PreTRM®

Sera Prognostics is a leader in health diagnostics, dedicated to improving pregnancy outcomes through precision medicine. The PreTRM® test is the only broadly validated, commercial blood-based biomarker test for early and individualized risk prediction of spontaneous preterm birth in asymptomatic, singleton pregnancies. It enables physicians to identify at-risk women during weeks 18-20 of pregnancy, allowing earlier intervention and improved outcomes.

Conference Call Information

Sera Prognostics will host a conference call and webcast to discuss these results and operational highlights. Details are available on the company’s investor relations website.

Conclusion

2025 was a pivotal year for Sera Prognostics, marked by the landmark PRIME Study publication, significant commercial and regulatory advances, and strengthened financial and leadership positions. The company now enters 2026 with a robust foundation for broader adoption of its PreTRM test, expanded payer coverage, and measurable impact on maternal and neonatal outcomes. These developments, especially the PRIME Study results and financing, could be material catalysts for SERA shares.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. All forward-looking statements are subject to risks and uncertainties as described in the company’s filings with the SEC.

View SERA PROGNOSTICS, INC. Historical chart here